|
KMID : 1084220210280040176
|
|
Journal of Rheumatic Diseases
2021 Volume.28 No. 4 p.176 ~ p.182
|
|
|
KOBIO, the First Web-based Korean Biologics Registry Operated With a Unified Platform Among Distinct Disease Entities
|
|
Kim Jin-hyun
Koh Jung-Hee
Choi Sung-Jae
Jeon Chan-Hong
Kwok Seung-Ki
Kim Seong-Kyu
Choi Chan-Bum
Lee Jae-Joon
Lee Chang-Hoon
Nam Eon-Jeong
Park Yong-Beom
Lee Shin-Seok
Kim Tae-Hwan
Park Sung-Hwan
Koh Eun-Mi
Yoo Dae-Hyun
Song Yeong-Wook
Kim Hyoun-Ah
Shin Ki-Chul
|
|
|
Abstract
|
|
|
|
The KOrean College of Rheumatology BIOlogics and targeted therapy (KOBIO) registry is a nationwide observational cohort that captures detailed data on exposure of patients to biologic and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs). This registry was launched in December 2012 with an aim to prospectively investigate clinical manifestations and outcomes of patients with rheumatoid arthritis (RA), ankylosing spondylitis, and psoriatic arthritis who initiated a biologic or targeted synthetic DMARD or switched to another. Demographic data, disease activity, current treatment, adverse events, terms based on Medical Dictionary for Regulatory Activities, and so on are registered for patients who are then followed up annually in a web-based unified platform. The KOBIO registry also recruits and collects data of patients with RA on conventional DMARDs for comparison. As of today, more than 5,500 patients were enrolled from 47 academic and community Rheumatology centers across Korea. The KOBIO registry has evolved to become a powerful database for clinical research to improve clinical outcomes and quality of treatment.
|
|
|
KEYWORD
|
|
|
Registries, Biological products, Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|